|
|
|||||||||||||||||||||||||||
  CytRx Corp (CYTR) CytRx is a biopharmaceutical research and development company focusing on oncology. Co. focuses on the discovery, research and clinical development of anti-cancer drug candidates that utilize LADR™ (Linker Activated Drug Release) technology platform to develop the accumulation and release of cytotoxic anti-cancer agents at the tumor. Co. has worked to develop and focused on the research and clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of tumors.
|
|
|||||||||||||||||||||||||||
Free CYTR Email Alerts:
CytRx Corp (CYTR) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.